Publications by authors named "Chaoneng He"
Objectives: The economic implications of combining rezvilutamide with androgen deprivation therapy (ADT) remain uncertain, despite the observed survival advantages compared with bicalutamide plus ADT. Therefore, this study evaluates the cost-effectiveness of rezvilutamide plus ADT as the first-line treatment of metastatic hormone-sensitive prostate cancer (mHSPC) from the perspective of the Chinese healthcare system.
Design: A partitioned survival model was developed to assess the cost-effectiveness of rezvilutamide combined with ADT.
Objectives: We aimed to evaluate and compare the risk of hematological adverse events (AEs) associated with CDK4/6 inhibitors using data from randomized controlled trials (RCTs) and Food and Drug Adverse Event Reporting System (FAERS) database.
Methods: The PubMed, Embase, and Cochrane Library databases were searched for RCTs related to abemaciclib, palbociclib, and ribociclib. A network meta-analysis (NMA) was conducted to compare the risks of hematological AEs, and a disproportionality analysis was performed to detect signals of hematological AEs.
Article Synopsis
- The study evaluated the cost-effectiveness of combining tislelizumab with chemotherapy versus using chemotherapy alone for treating advanced or metastatic oesophageal squamous cell carcinoma (OSCC) in China.
- A model was created to analyze costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) over a lifetime horizon, finding that the combination therapy provided additional QALYs at an ICER of $21,116.75 per QALY.
- Results indicated that while the combination is likely cost-effective, its affordability is influenced by the costs of specific drugs used in treatment, with its cost-effectiveness probability varying significantly based on different willingness-to-pay thresholds.
Omadacycline is an FDA-approved agent for community-acquired bacterial pneumonia (CABP). The purpose of this study is to evaluate the effectiveness of omadacycline for treating CABP patients infected with , including Methicillin-Resistant (MRSA) and Methicillin-Susceptible (MSSA), using pharmacokinetic/pharmacodynamic (PK/PD) analysis. Monte Carlo simulations (MCSs) were performed by utilizing omadacycline pharmacokinetic (PK) parameters, minimum inhibitory concentration (MIC) data, and PK/PD targets to calculate the probability of target attainment (PTA) and cumulative fraction of response (CFR) values for different dose regimens against MRSA and MSSA in CABP patients.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to analyze the pharmacokinetics of pegylated liposomal doxorubicin (PLD) in Chinese women with advanced breast cancer, focusing on population pharmacokinetic models for both liposomal and free forms of the drug.
- It involved 20 patients who received a single dose of 50 mg/m PLD, with plasma levels monitored using advanced chromatography techniques, and assessed drug-related adverse events (AEs) using established grading criteria.
- Results showed that both drug forms followed a one-compartment pharmacokinetic model, and while common AEs included nausea and stomatitis, stomatitis specifically correlated with the concentration of liposome-encapsulated doxorubicin
In our article ?Methadone switching for refractory cancer pain' (BMC palliative care, 2022) we explore the efficacy, safety and economics of methadone in treatment of patients with refractory cancer pain in China. Professor Mercadante provided a better interpretation of data regarding the opioid switching to methadone in the Matters Arising. In this article, we answered the questions in Mercadante et al.
View Article and Find Full Text PDFBackground: Cuproptosis, a recently discovered form of cell death, is caused by copper levels exceeding homeostasis thresholds. Although Cu has a potential role in colon adenocarcinoma (COAD), its role in the development of COAD remains unclear.
Methods: In this study, 426 patients with COAD were extracted from the Cancer Genome Atlas (TCGA) database.
Objectives: Poly (ADP-ribose) polymerase inhibitor (PARPi) have become a mainstay for the treatment of BRCA-mutant malignancies. PARPis are likely to be more effective but also bring an increase in costs. Thus, we aimed at evaluating the cost effectiveness of PARPis in the treatment of malignancies.
View Article and Find Full Text PDFBackground: Methadone is commonly considered an alternative opioid treatment for refractory cancer pain. This study aims to investigate the efficacy, safety, and cost of methadone in the treatment of refractory cancer pain.
Methods: A retrospective study was conducted in patients who used methadone for refractory cancer pain from April 2016 to December 2020 at a cancer specialized hospital.